Insulet (NSDQ:PODD) shares fell 4% today on break-even first-quarter results that were lower than analysts’ expectations. The company, however, raised the low end of its revenue guidance range to 16% to 20%. The range was previously 15–20%.
The Acton, Mass.-based wearable insulin delivery system developer posted a net loss of $0.0 million, or 0¢ per diluted share, on sales of $246.1 million for the three months ended March 31. For the sake of comparison, the company had a net loss of $2.1 million, or $(0.03) per diluted share, in the same quarter of 2020.
Adjusted to exclude one-time items, earnings per share were $0.00. Analysts were looking for EPS of $0.08 on sales of $247.1 million.
Get the full story from our sister site, Drug Delivery Business.